These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1715718)

  • 21. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data.
    Becker Y
    Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes.
    Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC
    Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.
    Takahashi H; Nakagawa Y; Pendleton CD; Houghten RA; Yokomuro K; Germain RN; Berzofsky JA
    Science; 1992 Jan; 255(5042):333-6. PubMed ID: 1372448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 26. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.
    Warren RQ; Wolf H; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules.
    Takeshita T; Kozlowski S; England RD; Brower R; Schneck J; Takahashi H; DeLisi C; Margulies DH; Berzofsky JA
    Int Immunol; 1993 Sep; 5(9):1129-38. PubMed ID: 8241055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoreactivity in HIV-infected individuals does not increase during vaccination with envelope rgp160.
    Lundholm P; Wahren M; Sandström E; Volvovitz F; Wahren B
    Immunol Lett; 1994 Jul; 41(2-3):147-53. PubMed ID: 8002030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes.
    Isaguliants M; Rudén U; Gilljam G; Wahren B
    Immunol Lett; 1994 Oct; 42(3):173-8. PubMed ID: 7534271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.
    Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH
    Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mixotope: a combinatorial peptide library as a T cell and B cell immunogen.
    Estaquier J; Gras-Masse H; Boutillon C; Ameisen JC; Capron A; Tartar A; Auriault C
    Eur J Immunol; 1994 Nov; 24(11):2789-95. PubMed ID: 7957571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous T-cell-helper-epitope peptides modulate immunogenicity and response specificity.
    Cease KB; Groeneveld LM; Probert WS
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1383. PubMed ID: 1281657
    [No Abstract]   [Full Text] [Related]  

  • 36. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual.
    Achour A; Lemhammedi S; Picard O; M'Bika JP; Zagury JF; Moukrim Z; Willer A; Beix F; Burny A; Zagury D
    AIDS Res Hum Retroviruses; 1994 Jan; 10(1):19-25. PubMed ID: 8179960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.
    Johnson RP; Trocha A; Buchanan TM; Walker BD
    J Exp Med; 1992 Apr; 175(4):961-71. PubMed ID: 1372650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted killing of yeast expressing a HIV-1 peptide by antibody-conjugated glucose oxidase and horseradish peroxidase.
    Chouchane L; Bringman T; Barbier S; Traincard F; Strosberg AD
    Immunol Lett; 1990 Sep; 25(4):359-65. PubMed ID: 1701163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.